Pages that link to "Q28276237"
Jump to navigation
Jump to search
The following pages link to Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry (Q28276237):
Displaying 50 items.
- Drug-induced liver injury: a clinical update (Q24617074) (← links)
- Drug-induced liver injury: present and future (Q24630227) (← links)
- Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury (Q26749054) (← links)
- RUCAM in Drug and Herb Induced Liver Injury: The Update (Q26771817) (← links)
- The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role? (Q26772999) (← links)
- MicroRNAs in Drug-induced Liver Injury (Q26781801) (← links)
- Drug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment Options (Q26781892) (← links)
- Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives (Q27690772) (← links)
- Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes (Q28243911) (← links)
- Drug Hepatotoxicity: Environmental Factors. (Q30275418) (← links)
- Chronic Cholestatic Liver Injury Attributable to Vedolizumab (Q30275619) (← links)
- Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review (Q30277969) (← links)
- Chronic liver injury induced by drugs: a systematic review. (Q30278737) (← links)
- Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record data (Q30582650) (← links)
- Eculizumab hepatotoxicity in pediatric aHUS. (Q33418797) (← links)
- Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: is the liver‐unspecific Naranjo scale precise enough to ascertain causality? (Q34195170) (← links)
- Acute liver injury associated with the use of herbal preparations containing glucosamine: three case studies (Q34525681) (← links)
- Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset (Q34848118) (← links)
- Hepatic safety of antibiotics used in primary care (Q35037383) (← links)
- Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles (Q35085772) (← links)
- Risk factors for idiosyncratic drug-induced liver injury (Q35168108) (← links)
- Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method (Q35644300) (← links)
- 'Les liaisons dangereuses': Hepatitis C, Rituximab and B-cell non-Hodgkin's lymphomas. (Q38638807) (← links)
- Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase (Q36378839) (← links)
- Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury (Q36668300) (← links)
- Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury (Q36744793) (← links)
- Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct (Q36799781) (← links)
- Repeated exposure to modern volatile anaesthetics may cause chronic hepatitis as well as acute liver injury (Q36884643) (← links)
- Idiosyncratic drug-induced liver injury: an overview (Q36984240) (← links)
- Assessment of drug-induced liver injury in clinical practice (Q37114105) (← links)
- Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis (Q37232721) (← links)
- Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibition (Q37279800) (← links)
- Practical guidelines for diagnosis and early management of drug-induced liver injury (Q37341906) (← links)
- Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models (Q37391731) (← links)
- Current concepts of mechanisms in drug-induced hepatotoxicity (Q37394799) (← links)
- Drug-induced liver injury following positive drug rechallenge (Q37419690) (← links)
- Review article: drug-induced liver injury in clinical practice (Q37726069) (← links)
- Regulatory causality evaluation methods applied in kava hepatotoxicity: Are they appropriate? (Q37790471) (← links)
- Idiosyncratic Drug-Induced Liver Injury: A Clinical Update (Q37806980) (← links)
- Drug-Induced Autoimmune-Like Hepatitis (Q37843783) (← links)
- Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity (Q37862739) (← links)
- Case definition and phenotype standardization in drug-induced liver injury. (Q37872195) (← links)
- Epidemiology of liver failure (Q37873065) (← links)
- Use of Hepatotoxic Drugs in Chronic Liver Disease (Q38004681) (← links)
- Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. (Q38095989) (← links)
- Intrahepatic cholestasis in common chronic liver diseases. (Q38127461) (← links)
- Idiosyncratic drug-induced liver injury: an update on the 2007 overview (Q38145274) (← links)
- Female gender as a susceptibility factor for drug-induced liver injury (Q38168331) (← links)
- Caspase 3 role and immunohistochemical expression in assessment of apoptosis as a feature of H1N1 vaccine-caused Drug-Induced Liver Injury (DILI). (Q38676495) (← links)
- Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature (Q38824550) (← links)